Baduanjin Versus Brisk Walking for Cognition in Schizophrenia

July 24, 2025 updated by: Chen Chyi-Rong, Chang Gung Memorial Hospital

Mindful Exercise Baduanjin Versus Brisk Walking for Cognitive Function in Patients With Schizophrenia

The current study intends to recruit participants with schizophrenia for the practice of Baduanjin, brisk walking, and health education after enrollment. The study also including a maintenance program. Cognitive and physical function assessments will be conducted before, after, and during follow-up tests. The research hypothesis posits that both Baduanjin and brisk walking will confer beneficial effects on various aspects of cognitive and physical functions.

Study Overview

Detailed Description

Cognitive function deficits are core features in patients with schizophrenia. These deficits need active intervention to prevent functional decline. Baduanjin and brisk walking show promise as interventions in patients with schizophrenia. This study investigated the effects of Baduanjin exercise versus brisk walking in patients with schizophrenia.

This study will be a single-blind, 3-arm, parallel, randomized controlled trial.

A total of 72 patients with schizophrenia will be enrolled and randomly assigned to the Baduanjin group, brisk walking group or control group. The intervention group will practice Badunjin exercise. While participants in brisk walking group will receive brisk walking at the same duration. The controls will watch videos that are not aimed at improving physical exertion. Maintenance programs will also be conducted for participants to encourage practicing in exercise after intervention. All group will undergo evaluation at three time points: baseline, immediately after intervention and 4-week follow up after intervention. The primary outcome will be cognitive function and physical function. Secondary outcomes will include mood, sleep quality, and quality of live.

Study Type

Interventional

Enrollment (Actual)

63

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kaohsiung, Taiwan, 833
        • Chang Gung Memorial Hospital, Kaohsiung Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Having a diagnosis of schizophrenia according to the DSM-5.
  2. Who will be above 20-65 years of age .
  3. Having a stable mental status without shift in medication and keep in same dose for at least one month.
  4. Being able to walk independently for 50 meters.

Exclusion Criteria:

  1. Serious physical conditions that will impede participation, such as cardiovascular disease, musculoskeletal disease or pulmonary system disease.
  2. Visual or auditory impairment that precludes completion of assessment.
  3. Acute psychosis requiring hospitalization.
  4. Presence of severe withdrawal or profound cognitive disability that cause difficulties in following instructions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Baduanjin
Parcipants will practice baduanjin exercise.
The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
Other Names:
  • Mindful baduanjin
Active Comparator: Brisk walking
Parcipants will perform brisk walking activities.
The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
Other Names:
  • aerobic walking
Other: health education
Parcipants will receive health education classes and watch sport related videos.
Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
Other Names:
  • video watching

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change scores of 6-minute walk test
Time Frame: Baseline, immediate after treatment, 4-week follow up
This test evaluates cardiovascular fitness and walking speed.
Baseline, immediate after treatment, 4-week follow up
Change scores of 30-second chair stand test
Time Frame: Baseline, immediate after treatment, 4-week follow up
This test evaluates muscular endurance of lower-extremities.
Baseline, immediate after treatment, 4-week follow up
Change scores of Timed up-and-go test
Time Frame: Baseline, immediate after treatment, 4-week follow up
This test evaluates functional mobility, agility and balance
Baseline, immediate after treatment, 4-week follow up
Change scores of dual task Timed up-and-go test (manual)
Time Frame: Baseline, immediate after treatment, 4-week follow up
This test requires carry a cup of water 3 cm from the top of the cup while performing the Timed up-and-go test. It evaluates dual task performance.
Baseline, immediate after treatment, 4-week follow up
Change scores of dual task Timed up-and-go test (cognitive)
Time Frame: Baseline, immediate after treatment, 4-week follow up
This test combine serial three counting and Timed up-and-go test simultaneously. It evaluates dual task performance.
Baseline, immediate after treatment, 4-week follow up
Change score of the Brief Assessment of Cognition in Schizophrenia (BACS)
Time Frame: Baseline, immediate after treatment, 4-week follow up
BACS is a battery of cognition tests that measure verbal memory, working memory, motor speed, verbal fluency, attention and processing speed, and executive function.The BACS is comprised of seven subtests: (1) the List Learning Test, (2) Digit Sequencing Test, (3) Token Motor Test, (4) Category Instance Test, (5) Controlled Oral Word Association Test, (6) Symbol Coding, and (7) Tower of London Test.
Baseline, immediate after treatment, 4-week follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change score of Depression, Anxiety Stress Scales-21 (DASS-21)
Time Frame: Baseline, immediate after treatment, 4-week follow up
DASS-21 is a self-report questionnaire that measure symptoms of depression, anxiety, and stress.
Baseline, immediate after treatment, 4-week follow up
Change score of Pittsburg Sleep Quality Index
Time Frame: Baseline, immediate after treatment, 4-week follow up
PSQI is a self-report assessment which contains 19 items to measure sleep quality
Baseline, immediate after treatment, 4-week follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Chen Chyi-Rong, Master, Chang Gung Memorial Hospital, Kaohsiung Branch

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 16, 2024

Primary Completion (Actual)

January 15, 2025

Study Completion (Actual)

January 15, 2025

Study Registration Dates

First Submitted

January 18, 2024

First Submitted That Met QC Criteria

January 18, 2024

First Posted (Actual)

January 26, 2024

Study Record Updates

Last Update Posted (Actual)

July 29, 2025

Last Update Submitted That Met QC Criteria

July 24, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Baduanjin exercsie

Subscribe